- The Federal Trade Commission on Friday sued three large U.S. health companies that negotiate insulin prices, arguing the drug middlemen boost their profits while “artificially” inflating costs for patients.
- The suit targets the three biggest so-called pharmacy benefit managers, UnitedHealth Group’s Optum Rx, CVS Health’s Caremark and Cigna’s Express Scripts, and their affiliated group purchasing organizations.
- The FTC may also recommend suing insulin manufacturers Eli Lilly, Sanofi and Novo Nordisk in the future.
When I have an option not to, I don’t. Unfortunately, the way health insurance works here, I often don’t have an option. With the insurance I had through my previous job, basically as soon as I requested a second refill, the pharmacy benefits would go “Hey, we won’t cover this anymore, unless you switch to 90-day refills via CVS Caremark.” At some points last year, that could easily have been $500-$1,000/month more for me to pay for my meds in order to keep getting them at the pharmacy two blocks away, and I just didn’t have it. Instead of going there and having pretty much all my prescriptions filled in an hour or less, I got to enjoy Caremark not letting me refill until the last minute, then encountering shipping delays with medications I really shouldn’t have been abruptly missing doses of.
Totally hear you and that’s what we got to legislate against. Thank you for telling another tale of their abuse.